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Abstract
Gene therapy is a novel promising approach for treating a spectrum of inherited and 
non-inherited disorders by delivering therapeutic genes to specific organs or tissues. Of 
the viral vectors that have been used to date to deliver the genes of interest, the adeno-
associated viral (AAV) vector appears to be the most safe and effective vehicle and 
has the ability to maintain long-term gene and protein expression following a single 
injection of the vector. Gene therapy studies using AAV vector have shown significant 
progress not only in animal models but also in human gene therapy with no known 
pathogenicity. While success has been achieved in gene therapy using AAV vector 
to deliver the target genes for inherited disorders, however, clinical trials are yet to 
begin to see whether gene therapy has promise for treatment of non-inherited diseases. 
This chapter describes AAV biology, viral structure, and cell entry mechanisms, with 
special emphasis on AAV tissue tropism achieved by manipulating different serotypes 
and capsid engineering. This chapter also discusses successful application of the AAV 
vector for non-inherited disorders in animal models with particular reference to liver 
fibrosis, outlining advantages, disadvantages, and future challenges that this therapy 
may face.
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1. Introduction
Gene therapy is a novel promising approach for treating a spectrum of inherited and non-
inherited disorders by delivering therapeutic genes to specific organs or tissues. Of the viral 
vectors that have been used to date to deliver the gene of interest, the adeno-associated viral 
(AAV) vector appears to be the most safe and effective vehicle and has the ability to main-
tain long-term gene and protein expression following a single injection of the vector. Gene 
therapy studies using AAV vector have shown significant progress not only in animal models 
but also in human gene therapy with no known pathogenicity. Recently, the Food and Drug 
Administration (FDA) has approved a pioneering gene therapy protocol using an AAV vector 
for a rare form of childhood blindness, the first such treatment cleared in the United States 
for an inherited disease. While success has been achieved in this field targeting inherited dis-
orders, however, clinical trials are yet to begin to see whether gene therapy has promise for 
treatment of non-inherited diseases. This chapter describes AAV biology, viral structure, and 
cell entry mechanisms, with special emphasis on AAV tissue tropism achieved by manipulat-
ing different serotypes and capsid engineering. This chapter also discusses successful applica-
tion of the AAV vector for non-inherited disorders in animal models with particular reference 
to liver fibrosis, outlining advantages, disadvantages, and future challenges that this therapy 
may face.
2. Adeno-associated virus
Adeno-associated virus (AAV) was discovered by Atchison et al. in 1965 from a pooled 
harvest of rhesus monkey kidney cell (RMK) cultures coinfected with simian adenovirus 
type 1 (SV15) [1]. This virus that could be observed as small DNA-containing particles was 
initially discovered as a contaminant of adenovirus preparations, and thus, it was named 
adeno-associated virus. However, AAV belongs to a genus of the parvoviruses, now known 
as dependoviruses [2]. AAV is replication defective and depends on a helper virus for effec-
tive and productive replication in mammalian cells. Generally, adenovirus or herpes viruses 
are considered to be the helper viruses for AAV to continue its life cycle. Early research on 
AAV has shown that this virus does not cause any disease in man even though it appears that 
it persists in humans along with its helper virus, particularly adenovirus [2]. In 1969, AAV 
was shown to possess several advantages in experimental systems including its small DNA 
genome of approximately 5 kb, packaging of plus and minus strands into individual particles, 
and most importantly, it is present as a defective virus [3]. During the first 20 years after its 
discovery, its genome structure, growth cycle, and latency were described. In the early 1980s, 
the genome sequencing of AAV serotype 2 (AAV2) was completed by Srivastava and col-
leagues [3]. This facilitated the generation of the first recombinant AAV vectors using AAV2 
by the mid-1980s. Thereafter, studies using AAV were used for gene transfer in mammalian 
cell cultures. Subsequently, evidence of clinical safety has encouraged the researchers to use 
AAV vectors in clinical trials for various inherited disorders [4].
The AAV2 is a non-enveloped virion with a genome consisting of a single-stranded DNA 
(ssDNA) which is enclosed by a spherical protein shell about 20 nm in diameter [5, 6], with 
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a density of 1.41 g/cm3 [6, 7]. The AAV genome is made up of 4675 nucleotides flanked by 
inverted terminal repeats (ITRs). Each ITR is 145 nucleotides in length and forms a T-shaped 
hairpin structure by self-base pairing utilizing the first 125 nucleotides [3, 8]. Viral replication 
(Rep) and capsid (Cap) genes responsible for encoding four non-structural proteins, such as 
Rep40, Rep52, Rep68, and Rep78, and three structural proteins, such as VP1, VP2, and VP3, 
respectively, are located between the two ITR regions. The structural proteins, VP1, VP2, and 
VP3, are arranged in a ratio of 1:1:10 to form the icosahedral symmetrical shape of the virus 
[6, 9]. It has been reported that the VP1 protein is essential for infection [6, 10], whereas VP2 
is the major protein responsible for nuclear transfer of the capsid proteins. Of note, the VP3 
subunit is the most abundant protein in the capsid responsible for the binding of the virus to 
cell surface receptors [6, 11] and viral particle formation in the host cell [12].
3. AAV-host cell interaction
Heparan sulfate proteoglycan (HSPG) is the first identified primary receptor that AAV2 binds 
when infecting cells [6, 13]. The initial hypothesis was that the HSPG-binding site is located 
within the capsid protein VP3 [14], and this hypothesis was further supported by a mutational 
analysis performed by Wu and colleagues in year 2000 [11]. Wu et al. showed that there are 
two VP3 amino acid clusters of AAV2 that are involved in HSPG binding [11]. HSPG is not 
the only receptor type involved in AAV2 binding to a host cell, but there are one or more 
coreceptors which facilitate AAV cellular entry. Interestingly, αvβ5 integrin was identified 
as a coreceptor for internalization of AAV2 virions by Summerford and colleagues [15]. In 
cell studies, the chelating agent ethylenediaminetetraacetic acid (EDTA) was used to disrupt 
integrin function and results showed a notable reduction in AAV2 infection, suggesting that 
AAV2 uses αvβ5 integrin as a secondary receptor to mediate viral entry. Moreover, Qing and 
colleagues identified that human fibroblast growth factor receptor 1 (FGFR1) is also essential 
for viral entry into the host cell [16] and acts as a coreceptor for successful infection by AAV [6].
Although AAV2 is the most extensively studied serotype of AAV, there are several other AAV 
serotypes which have been evaluated for their binding characteristics to cellular receptors. 
It was recently shown that AAV serotypes 3 [17] and 13 (VR-942) [18] utilize HSPG as the 
primary cell surface receptor for cell entry, while AAV serotypes 1, 4, 5, and 6 [18–20] utilize 
N-linked and O-linked α2–3 and α2–6 sialic acids. AAV9 interacts with N-terminal galactose 
as the primary receptor [21] and also interacts with secondary coreceptors for facilitating cell 
entry, such as integrins [15, 22] FGFR1 [16], hepatocyte growth factor receptor (c-Met) [23], 
and laminin receptor [24]. Despite all these known pathways for AAV infection, no common 
primary receptor for all the AAV serotypes had been identified. Recently, Pillay and colleagues 
[25] used a library of mutagenized haploid HAP1 cells to create knockouts of nearly all non-
essential genes in the human genome. This knockout library was exposed to recombinant 
AAV2-RFP (AAV2-red fluorescent protein), and a gene that was most significantly enriched 
in the screen was identified. This receptor named “AAV receptor (AAVR)” is characterized 
as a type I transmembrane protein which contains a MANSC domain, five polycystic kid-
ney disease (PKD) domains, and a C6 region near the N terminus. These findings have been 
validated using an AAVR knockout cell line which demonstrated a resistant to infection by 
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almost all AAV serotypes, whereas restoring recombinant AAVR gene in the AAVR knockout 
cells restored the ability of AAVs for successful infection. Furthermore, AAVR gene knockout 
mice demonstrated robust resistance to AAV9 infection. This important discovery implicates 
the AAVR as a universal primary receptor for all AAV serotype infection [6].
4. Cell entry mechanism of AAV
The major cell entry mechanism for AAV is via endocytosis utilizing clathrin-coated pits, 
although other minor mechanisms are possibly involved in this process. However, these 
alternative minor mechanisms are yet to be confirmed [6]. Upon AAV binding to its cell 
surface receptors, it stimulates intracellular signaling pathways, which in turn stimulates 
internalization of AAV. This phenomenon can be clearly explained using the mechanisms 
reported for AAV2 host cell interaction. It was shown that attachment of AAV2 to HSPG and 
αVβ5 integrin resulted in the activation of Rac1, an intracellular small guanosine triphosphate 
(GTP)-binding protein, and phosphoinositide 3-kinase (PI3K) in HeLa cells within 5 minutes 
of AAV2 infection [26]. Furthermore, inhibition of Notch1 by siRNA, a transmembrane recep-
tor known to be involved in the activation of Rac1 and PI3K, was reported to decrease cell 
transduction by AAV2 [27], suggesting that the Rac1-PI3K pathway is necessary to initiate 
endocytosis of AAV2. Direct injection of AAV into the cytoplasm and nucleus of cells results 
in a significant lower infection rate than cells that are simply exposed to virus [28], suggesting 
that the processing of AAV virion through endosomal compartments is a critical initiating 
step for transduction following endocytosis.
In addition, transduction efficiency of AAV is largely dependent on the endosomal 
pH. Changing the pH to acidic (pH 4–6) inside the endosomal compartment facilitates trans-
duction of AAV, whereas blocking acidification during endosomal processing decreases the 
rate of transduction [29–31]. Also, the application of different classes of proteasome inhibitors 
such as tripeptidyl aldehydes and N-acetyl-l-leucyl-l-leucyl-l-norleucinal (LLnL) and the 
anthracycline compounds such as doxorubicin increases the rate of viral translocation to the 
nucleus [32]. Furthermore, LLnL appears to increase AAV2 capsid ubiquitination that results 
in augmented gene transfer in different cell types [33], suggesting a mechanism by which 
these inhibitors increase transduction may be related to ubiquitination. AAV must exit from 
the endosome first before translocating to the nucleus. Prior to escape from the endosome, 
AAV undergoes a conformational change leading to the exposure of the unique N-terminal 
ends of VP1 and VP2, which contains a domain of phospholipase A2 (PLA2) [34], an enzyme 
that breaches the endosomal membrane and thereby facilitates efficient endosomal escape 
of viral particles. Upon endosomal escape, AAV enters the nucleus as an intact particle [28] 
and uncoating then occurs inside the nucleus. However, nuclear transport of AAV is a slow 
process, approximately only 1–2% of internalized AAV enters and expresses in the nucleus, 
and the whole entry process takes about 2–13 h [35]. Thus, most viral particles which fail to 
translocate are located outside or away from the nucleus.
The viral particles that fail to translocate into the nucleus are eventually degraded by host 
proteasomes in the cytoplasm and presented as antigen to cytotoxic T cells via the major 
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histocompatibility complex (MHC) class I pathway [36]. Although there are several studies that 
have investigated the nuclear entry of AAV, the mechanism by which AAV translocates into the 
nucleus is still unclear. Because AAV is a small virus with a diameter of around 20 nm, it has 
been suggested that the virion enters the nucleus using the nuclear pore complex (NPC) [37].
Furthermore, the nuclear entry of AAV is dependent on importin-β, a nuclear import pro-
tein that has been shown to play a key role in facilitating the binding of viral particles to 
host nuclei in other viral infectious pathways [38, 39]. Another study using single-point 
edge excitation sub-diffraction (SPEED) microscopy, a form of super-resolution imaging, to 
track single AAV particles revealed that approximately 17% of AAV particles were imported 
through the NPC successfully to the nucleus [40], reinforcing the importance of the NPC in 
AAV nuclear transfer. Interestingly, there is further evidence that nucleolin, a protein that 
shuttles between cytoplasm and nucleus, specifically binds to AAV capsid, which suggests 
that nucleolin may act as a nuclear receptor for AAV particles as well [41]. Upon entry into 
the nucleus, the ssDNA of AAV genome is converted to double-stranded DNA (dsDNA) 
using nuclear machinery of the target cells for transcription of the transgene [42]. The syn-
thesis of second DNA strand has been considered as a rate-limiting factor for the onset and 
efficiency of transgene expression in ssAAV vectors [43]. As a result, second-generation AAV 
vectors with a dsDNA, also known as self-complementary AAV (scAAV) vectors, have been 
developed to improve the transduction and transcription efficiency. In the past decade, sev-
eral studies have shown that new scAAV vectors provide safe, reliable, and organ-specific 
transduction both in vitro [44–46] and in vivo [46–49]. This suggests that the limitations asso-
ciated with cell transduction using ssAAV genome can be overcome by the use of scAAV 
vectors in gene therapy.
5. AAV serotypes and tissue tropism
To date, a total of 12 naturally occurring AAV serotypes have been discovered from both 
human and non-human primates (Table 1). These serotypes are able to infect cells of diverse 
tissue types. Interestingly, the tissue specificity is determined by the capsid serotype. The 
existence of a variety of serotypes with different infectivity rates and tissue specificity 
makes AAV one of the most promising candidates in gene therapy research. By develop-
ment of different AAV pseudotypes, researchers have been able to obtain unique cellular 
tropism and high transduction efficiency. All AAV serotypes share at least 50% sequence 
homology. However, serotype AAV5 has the most divergent amino acid capsid sequence, 
and AAV4 also shows a considerable degree of divergence [50]. Surprisingly, this sequence 
diversity between serotypes is not scattered but primarily located in the looped out domains 
of the capsid protein [51]. However, comparative studies of AAV serotypes found that this 
sequence variability may not be responsible for the differences in infectivity rates and tissue 
specificity. AAV serotype 2 is most widely used in gene therapy research. Several studies 
have investigated gene expression and tropism in vivo mediated by different AAV sero-
types and identified that they differ broadly in transduction efficacies and tissue tropism. 
A comparative study of AAV serotypes 1–9 mediated transgene expression after systemic 
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tail vein injection in mice showed that each AAV serotype profoundly differs in its ability to 
transduce organs, with AAV9 having the highest and fastest onset of transgene expression, 
highest viral genome copies, and the broadest tissue tropism, as determined by luciferase 
images [52]. Conversely, AAV3 and AAV4 are the slowest in targeting tissues, and among 
all the serotypes, AAV2, 3, 4, and 5 have the lowest transduction efficiency. The liver is the 
most common organ transduced by nearly all AAV serotypes with AAV7 and AAV9 showing 
the strongest tropism. Moreover, AAV9 is the most efficient serotype in reaching the heart 
and brain, followed by AAV4 and AAV8, respectively [52]. Of note, AAV serotype 8 (AAV8) 
shows a significantly greater liver transduction efficiency than the other AAV serotypes, and 
therefore, this serotype has been developed to use as a gene therapy vector for hemophilia A 
and familial hypercholesterolemia [53].
AAV 
serotype
Characteristics Tissue tropism
AAV1 Shares 99% homology with AAV6 serotype [50] Liver, heart, skeletal muscle [52]
AAV2 The most commonly used serotype
Close homology to all serotypes except AAV 4, 
5, 11, and 12 [50]
Low transduction efficiency [52]
Liver, heart, muscle [52]
AAV3 Low transduction efficiency
Slow in targeting the tissues [52]
Heart, liver [52]
AAV4 Close homology to AAV11 (82%) and AAV12 
(79%) serotypes [50]
Low transduction efficiency
Slow in targeting the tissues [52]
Lung, heart, liver, central nervous system [52, 134]
AAV5 The most divergent serotype (shares only 
53–59% homology to other serotypes)
Low transduction efficiency [52]
Liver [52]
AAV6 Shares 99% homology with AAV1 serotype [50] Liver, heart, skeletal muscle [52]
AAV7 Fast in targeting the tissues [52] Liver, skeletal muscle [52]
AAV8 93% homology to AAV10 serotype [50] Heart, liver, brain, muscle (second most efficient 
serotype reaching the brain) [52]
AAV9 Fast in targeting the tissues [52] Liver, heart, brain, lung, skeletal muscle (serotype with 
the broadest tissue tropism and most efficient in reaching 
the brain) [52]
AAV10 93% homology to AAV8 serotype [50] Liver, heart, muscle, lung, kidney, uterus (with 
pseudotype AAV2/10) [135]
AAV11 Close homology to AAV4 serotype [50] Muscle, kidney, spleen, lung, heart, stomach (with 
pseudotype AAV2/11) [135]
AAV12 Close homology to AAV4 serotype [50] Muscle, salivary glands [136]
Table 1. Characteristics and tissue tropism of AAV serotypes in the mouse.
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6. Molecular engineering of AAV capsid
There are several challenges for AAV serotypes to exert their therapeutic potential in target 
organs including the need for high vector doses for efficient delivery, pre-existing antiviral 
immunity in the host, and the lack of cell type-specific tropism leading to off-target transduc-
tion [6]. One way to overcome these limitations is to randomly generate capsid mutants from 
a library to extend the capability of the traditional AAV vector by increasing its cell transduc-
tion efficiency for specific cell types and its ability to escape from antibody neutralization.
One approach used to create a mutant library is DNA shuffling, a strategy in which the open 
reading frame of capsid genes of different AAV serotypes is fragmented by nucleases. This is 
followed by random ligation, resulting in new and random combinations of capsid sequences. 
These new molecular-enhanced AAV vectors exhibit a broad range of cell tropism with numer-
ous functional differences between chimeras and their parent serotypes. Consequently, there 
is potential to produce unlimited numbers of new AAV variants with novel gene delivery 
properties. This method of AAV capsid engineering was first described in 2008 by Grimm and 
colleagues [54] and has become a commonly used technique over the years. More recently, 
Lisowski and colleagues utilized a humanized mouse model to perform serial selection using 
a human-specific replication competent viral library composed of DNA-shuffled AAV capsids. 
After four rounds of selection, they identified a novel chimeric capsid variant composed of 
five different parental AAV capsids [55]. Of these, LK-03, which efficiently transduced human 
primary hepatocytes both in vitro and in vivo, was found to be a human liver cell-specific AAV 
serotype [55]. This study has opened up a new avenue to validate therapeutic potential of an 
AAV capsid variant in preclinical studies using human primary cell xenotransplanted models 
prior to commencing clinical studies.
In addition, a study using in silico ancestral sequence reconstruction (ASR) of AAV capsid 
protein generated nine functional putative ancestral AAVs. In this study, Zinn and colleagues 
also identified Anc80, the predicted ancestral sequence of the widely used AAV serotypes 1, 
2, 8, and 9 and showed that Anc80 is a highly potent in vivo gene therapy vector compared 
to AAV2 and AAV8 for targeting liver, muscle, and retina in mice [56]. Nevertheless, Anc80 
demonstrated a high stability and no toxicity in several safety studies carried out in mice. This 
synthetic viral vector has been evaluated in non-human primates (rhesus macaques), which 
demonstrated a superior expression of Anc80 in monkey liver following Anc80 administra-
tion compared to control monkeys injected with AAV8. Hence, future studies may also rely 
on the use of Anc80, in particular for liver-directed gene therapy studies.
7. AAV as a safe vector in gene therapy
It has been shown that AAV viral proteins cause a minimal immunogenic response, and at the 
same time, it can yield prolonged expression of therapeutically relevant genes/proteins. Also, 
when comparing to the other potential viral vectors such as lentiviral vectors, AAV possesses 
a reduced proinflammatory risk and has been considered as one of the most promising gene 
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transfer vectors for in vivo gene therapy [57]. However, in some experimental settings, it was 
reported that immune responses generated by AAV administration appear to compromise the 
outcomes of AAV-mediated gene therapy. Thus, several factors may determine the occurrence of 
immune responses against the AAV proteins, including the route of administration, dose, sero-
type, host species, transgene and expression cassettes, and pre-existing immunity to AAV [6, 58].
It has been suggested that AAV activates mouse and human plasmacytoid DCs to produce 
type 1 interferon via a TLR9-MyD88 pathway, resulting in induction of adaptive immune 
CD8+ T cell responses to AAV capsid and the transgene [58]. In addition, different adminis-
tration routes for AAV2-mediated ocular gene therapy induced varying immune responses. 
For instance, intravitreal administration of an AAV2 vector, which led to transduction of the 
inner retina, triggered a humoral immune response to AAV2 capsid; however, no effect was 
observed following subretinal administration and subsequent repeated injections [59]. Animal 
studies have suggested that the presence of neutralizing antibodies could compromise AAV 
transduction in vivo following systemic administration [60, 61]. These findings are potentially 
important for translation of AAV gene therapy from animal studies to clinical trials due to the 
large prevalence of AAV neutralizing antibodies in humans.
Due to natural exposure to wild-type AAV early in life, a significant proportion of human 
population have humoral immunity to the AAV capsid, primarily AAV1, 2, 3, and 5 [62, 63]. Of 
note, among the most commonly used AAV vectors, the most prevalent anti-AAV antibodies 
in humans are AAV2 followed by anti-AAV antibodies to AAV1 [64], while the least prevalent 
are for AAV7 and AAV8. It has been shown that rAAV vectors, including serotypes 1, 2, and 
5 can transduce dendritic cells (DCs) and generate immune responses to transgene products 
[65, 66]. Interestingly, another study, which evaluated the differential immune responses to 
the transgene products from rAAV1 and rAAV8 vectors using a hypersensitive autoimmune 
mouse model, revealed that unlike AAV1 vectors, AAV8 vectors were unable to transduce 
dendritic cells (DCs) and elicit transgene-specific immune responses efficiently, resulting 
in induction of immune tolerance to transgene products [67]. Different properties of these 
vectors imply tremendous potential in different applications, where an immune response to 
transgene is to be either elicited or avoided.
8. AAV vector transduction efficiency—male versus female
Recombinant AAV vector transduction efficiency clearly depends on the gender. This fact 
has been specifically shown in the liver and the brain in murine models. A study carried 
out by Maguire and colleagues has shown that the vector transduction efficiency using AAV 
serotype 9 was found to be different in the brain and the liver between male and female mice 
[68]. This study revealed a higher transgene expression in the brain of females compared with 
male mice, whereas a higher transgene expression was observed in the liver of male mice 
compared with female mice. In line with this study, Davidoff and colleagues revealed that 
when compared with female mice, transgene expression after liver-targeted delivery of AAV2 
and AAV5 particles was 5- to 13-fold higher in male mice [69]. In addition, they found that 
transduction efficiency was dramatically reduced by castration in male mice, whereas oopho-
rectomy in female mice did not significantly influence rAAV transduction [69]. Moreover, 
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administration of 5α dihydrotestosterone in female mice prior to rAAV injection enhanced 
stable hepatocyte gene transfer to levels observed in male mice, suggesting rAAV vector 
transduces hepatocytes via an androgen-dependent pathway [69].
In addition, there is evidence to demonstrate the distinctly different patterns of persistence of 
rAAV-eGFP (enhanced green fluorescent protein) expression across the hepatic lobule in male 
and female mice. Female mice retained a predominantly perivenous pattern of expression, 
whereas male mice had shown an inversion of this pattern with preferential loss of perive-
nous expression and relative retention of periportal expression [70]. Therefore, these sexually 
dimorphic patterns of genome persistence could have significant implications for the long-
term therapeutic efficacy of rAAV-mediated gene transfer in man, particularly in the context 
of correction of liver functions showing metabolic zonation [70].
9. Production and modification of AAV
The AAV serotype 2 was the first AAV vector used for gene transfer applications. This particu-
lar vector was chosen primarily because of its broad tropism, efficient transduction with stable 
and long-term transgene expression with minimal inflammation, and immune responses in 
a number of organs, such as the brain [71], retina [72], and skeletal muscles [73]. Liver is the 
other major organ which is targeted for rAAV2 gene delivery strategy because hepatocytes 
are easily accessible to vectors injected into the circulation through large pores in liver capil-
laries. Although results in the liver have been less consistent, a number of studies demonstrate 
a successful transduction of rAAV2 vector with persistent transgene expression in the liver 
using a single dose [74], and approximately 5% of hepatocytes were transduced following 
rAAV2 vector injection [75]. Of note, a study which was undertaken by Snyder and colleagues 
provided the most impressive results by achieving sustained and therapeutic levels of factor 
IX in hemophilia B, with no associated toxicity in both canine and murine models [75, 76].
The discovery of novel strategies for pseudotyping, recombination of AAV constructs into 
capsids of alternative serotypes, and the development of scAAV vectors which effectively 
alter tissue tropisms with enhanced transduction efficiency [77] has opened up new avenues 
to produce more attractive vectors for use in clinical applications including hemophilia B, 
Parkinson’s disease, and rheumatoid arthritis [78]. Among all novel recombinant AAV sero-
types, AAV2 genome construct pseudotyped with capsid 8 (AAV2/8) is one of the most effi-
cient vectors for hepatic gene transfer. In addition, it has greater liver transduction efficiency, 
with fourfold more genomes per transduced cell, when compared with other pseudotyped 
vectors [6, 79]. Moreover, it has an excellent transduction rate (95%) in hepatocytes of the 
mouse liver via intraportal vein injection [80]. In line with this, the development of scAAV 
vectors further enhances the transduction efficiency to the liver [81], suggesting that the con-
version of single-stranded AAV genome into double-stranded form for gene therapy studies 
appears to be beneficial since this procedure can avoid the need to assemble second DNA 
strand for transgene expression in vivo [6, 46, 82].
The most widely used method to produce and purify recombinant AAV particles for preclinical 
applications is the triple transfection method using HEK293 cells, which requires the use of an 
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AAV replication and capsid plasmid that provides Rep78, Rep68, Rep52, and Rep40 proteins 
necessary for vector genome replication and VP1, VP2, and VP3 capsid proteins, the vector 
DNA plasmid with the inverted terminal repeat-transgene cassette, as well as the adenovirus 
(Ad) helper plasmid [83, 84]. In addition, HEK293 cells have been engineered to provide adeno-
virus helper genes in trans such as E1a and E1b55k for AAV assembly. The key advantage of 
this method is that AAV particles can be efficiently made with genes supplied by Ad helper and 
HEK293 cells without the need to use replication competent adenovirus [84] (Figure 1). In addi-
tion, to improve tissue tropism, the AAV genomes can be pseudotyped with a desired capsid 
protein. Following 48–72 h transfection, the cell homogenate is purified, followed by the assess-
ment of AAV quality control including genome titer [85], infectious and transducing properties, 
and integrity of the packaged AAV genome [86]. This is schematically illustrated in Figure 1 
where AAV2 genome is pseudotyped with capsid 8 (AAV2/8) to increase liver specificity [87].
10. Pros and cons of AAV gene therapy
A successful gene therapy approach should deliver an appropriate amount of a therapeutic gene 
into the target tissue without substantial toxicity while achieving long-term gene expression. Of 
all currently available viral vectors including retroviral, lentiviral, adenoviral, and AAV vectors, 
the AAV is a unique non-pathogenic viral vector with broad tissue tropism and has the potential 
Figure 1. Schematic representation of the assembly of AAV2 genome pseudotyped with liver-specific AAV serotype 8 
and liver-specific promoters in HEK293 cells. Liver-specific rAAV2/8-ACE2 viral particles are produced by transfecting 
HEK293 cells with rep2/cap8 plasmid, Ad helper plasmid, and a plasmid carrying AAV2 inverted terminal repeat-ACE2 
cassette with liver-specific promoters. Recombinant AAV2/8-ACE2 viral particles are purified from cell homogenate 
48–72 h post transfection, followed by assessment of AAV quality, genome titer, infectious and transducing properties, 
and integrity of the packaged AAV genome [87].
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to be the leading vector for future gene therapy studies [88]. Unlike recombinant adenoviral vec-
tors which yield high initial gene expression that diminishes rapidly due to immune clearance, 
the AAV vector-based gene expression is persistent. In addition, as AAV vectors were derived 
from a parental virus with no known pathogenesis which is replication defective, they do not 
carry a risk of infecting patients with a pathogenic wild type virus. In addition, AAV vectors 
mediate a minimal cell-mediated immune response, which is favorable for the persistence gene 
transduction to the host cells. At the same time, AAV-based vectors are able to transduce a wide 
range of host cells including both dividing and non-dividing cell types [88, 89]. A prominent dis-
advantage associated with AAV compared to the other viral vectors is its small packaging size, 
which limits the size of the transgene to be delivered using the vector. However, novel molecular 
engineering methods have the potential to overcome these limitations, and thus, genetically 
engineered AAV is poised to become the leading vector for future gene therapy in humans.
11. Gene therapy using AAV vectors for inherited disorders
Many studies have explored the therapeutic potential of these engineered AAV vectors for a 
number of inherited disorders. After several decades of experimental studies, the first suc-
cessful human gene therapy protocol using AAV serotype 1 vector was approved in 2012 by 
the European Commission (EU) for the treatment of patients with lipoprotein lipase defi-
ciency (LPLD), an extremely rare genetic disorder [90]. This was a milestone achievement for 
researchers who have been working to develop successful gene therapy protocols for inher-
ited human disorders. The therapy was introduced under the trade name Glybera® (alipogene 
tiparvovec) by UniQure. However, after 5 years of the launch of the world’s first approved 
gene therapy, UniQure has not renewed its EU license in 2017 and ceased to produce Glybera 
for use because of the expensive nature of the treatment protocol [91]. However, it was unfor-
tunate that UniQure has discontinued its production despite the first LPLD patient treated 
with alipogene tiparvovec showing improvement of quality of life without abdominal pain 
and pancreatitis attacks for 18 months [92]. UniQure, however, has endeavored to develop 
gene therapy for hemophilia B.
The most common clinical trials based on AAV therapy in recent years have been in hemo-
philia B, a blood clotting disorder caused by a defect in the gene encoding coagulation Factor 
IX (FIX), leading to a deficiency of FIX. The only treatment available for this disease is lifelong 
intravenous infusion of FIX concentrates. Although this treatment is effective as a preventive 
medicine, it is not curative. In addition, the treatment is invasive, inconvenient, and very 
expensive, thus not affordable for most patients with hemophilia B, resulting in a reduction 
in life expectancy for those patients with a severe bleeding phenotype [93]. Similar to the FIX 
concentrates, there are clotting formulations with longer half-life which represents a major 
advance but still require lifelong intravenous administration. Robust preclinical results using 
AAV-based therapy in two murine [74, 94] and three canine models of hemophilia B [95–97] 
demonstrated long-term expression of FIX, with no significant liver toxicity and with no 
FIX-specific antibodies detected following muscle- or liver-directed injections. A follow-up 
study demonstrated an induction of immune tolerance in mice after hepatic gene transfer by 
rAAV expressing human FIX (rAAV-hFIX), which is mediated by regulatory CD4+ T cells, 
resulting in suppression of human FIX antibody formation [6, 98]. Based on the results from 
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animal studies, the world first clinical trial using rAAV2-hFIX vector in humans via intramus-
cular route has been conducted [99]. The results indicated that the transduction of muscle 
tissue was successful; however, circulating plasma FIX levels in all patients were less than 
the required level for a therapeutic effect (<2% of normal). In a subsequent clinical study, the 
delivery target was switched to the liver, the normal site of FIX synthesis. Although rAAV2-
mediated hFIX gene transfer to the liver-mediated therapeutically relevant expression levels 
[100], the expression persisted for less than 8 weeks.
Recent study by Nathwani and colleagues demonstrated the AAV8 serotype as a more 
effective vector for liver-directed hemophilia B gene therapy [101]. In this study, six severe 
hemophilia B patients received a single injection of pseudotyped AAV2/8-hFIX vector at three 
escalating doses (high, intermediate and low), with two patients per dose and no immuno-
suppressive was given. Patients were subsequently followed for up to 16 months. All patients 
have achieved AAV2/8-mediated expression of FIX at above the therapeutic threshold, 
ranging between 2 and 11% of normal levels, and the increase in FIX serum level was dose-
dependent. Four out of six patients discontinued their prophylactic treatment with hFIX con-
centrates without having spontaneous hemorrhage, whereas the other two patients continued 
to receive hFIX concentrates but extended the interval between hFIX treatments. This was 
the first liver-directed AAV gene therapy trial to show sustained therapeutic FIX levels and 
improved clinical outcomes in patients with hemophilia B. However, in patients who received 
the highest dose of vector, T cell-mediated clearance of AAV-transduced hepatocytes was 
observed, with associated elevation of liver enzyme levels. This response has been overcome 
by a short course of glucocorticoids, without the loss of hFIX expression.
Nathwani and colleagues later conducted a follow-up study to evaluate the long-term safety 
and efficacy of AAV2/8-hFIX therapy in the same cohort of hemophilia B patients [93]. Of note, 
this monitoring study also included addition of four new patients, each of whom received the 
high dose of vector. Consistent with their previous findings, a single intravenous injection of 
vector resulted in an increase in plasma FIX activity from less than 1% to sustained level of up to 
6% of the normal value in all 10 patients, and this remained stable for up to a period of 4 years. 
Additionally, substantial clinical improvements were achieved in all patients, including 
significant reductions in number of spontaneous hemorrhage and annual number of pro-
phylactic treatment with FIX concentrates. Not surprisingly, there was a dose-dependent, 
asymptomatic increase in both the serum alanine transaminase (ALT) level and increase in 
anti-AAV capsid neutralizing antibody level, which led to a gradual decline in FIX levels, 
suggesting transduced hepatocyte destruction. There was a transient increase of ALT levels in 
all patients which resolved with administration of a single course of prednisolone, after which 
no recurrent elevation of serum ALT in patients was observed.
A recent clinical trial completed using ssAAV vector consisted of a bioengineered capsid, liver-
specific promoter, and FIX Padua (FIX-R338L) in 10 men with hemophilia B who had FIX coag-
ulant activity of 2% or less of the normal also showed a success with no serious adverse events 
during or after vector infusion [102]. These patients were followed up to 492 days (16 months). 
The results showed that 8 of 10 patients did not require the regular treatment with FIX con-
centrates, and bleeding episodes were not reported in 9 patients after the vector treatment. 
Overall, there was a significant reduction in annual bleeding rate in patients treated with AAV-
FIX-R338L. Although there were two patients who developed asymptomatic increase in liver 
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enzyme levels, they were recovered after a short-term prednisone treatment. Of all participants, 
only one patient had been treated with FIX concentrates who was diagnosed with an advanced 
arthropathy at baseline. However, the use of FIX concentrate was reduced to 91% compar-
ing to the status before vector infusion. Additional clinical trials are underway with AAV2/8-
hFIX (NCT00979238) and FIX-Padua (NCT01687608), which will provide more information on 
safety and efficacy of the therapy [103]. Overall, the results from these studies suggest that gene 
therapy has the potential to significantly improve disease phenotype in hemophilia B patients.
It is of significance that for the first time, the US Food and Drug Administration (FDA) has 
approved a pioneering gene therapy protocol using an AAV vector for a rare form of childhood 
blindness in 2017 as the first such treatment cleared in the United States for an inherited dis-
ease. The disease known as Leber congenital amaurosis (LCA) develops due to mutations in the 
RPE65 (retinal pigment epithelium-specific 65-kDa) gene, causing a severe form of inherited 
retinal blindness in infants and children. Several independent studies [104–106] using rAAV2/2 
expressing RPE65 complementary DNA (cDNA) have provided preliminary evidence of short-
term safety and efficacy in this disorder. Further studies by Cideciyan and colleagues showed 
a significant efficacy of human retinal gene transfer with rAAV2-RPE65 vector with transgene 
expression for up to 1 year post treatment [107]. Also, they have proven the treatment as a safe 
therapy by evaluating the safety parameters obtained through regular standard eye exami-
nations, physical examinations, routine hematology, serum chemistries, coagulation param-
eters, and urinalysis. This particular FDA-approved gene therapy (LUXTURNA) (voretigene 
neparvovec-rzyl) is to be used in patients with confirmed biallelic RPE65 mutation-associated 
retinal dystrophy. This approval is considered as a milestone of AAV vector-associated gene 
therapy research and further encourages researchers to develop successful vectors to deliver 
therapeutic genes for number of diseases where there is no effective medical treatment.
12. Gene therapy for non-inherited disorders
There have been many advances in identification of the mechanisms involved in chronic 
organ damage which opened up avenues for gene therapy studies [108]. While a plethora 
of preclinical and clinical studies over past several decades has focused on developing gene 
therapy for inherited disorders, despite several preclinical studies in animal models, there 
have been only a few clinical trials that have been undertaken to investigate therapeutic 
efficacy of gene therapy for non-inherited diseases. A recent study shows that telomerase 
expression using AAV9 vectors exerts therapeutic effects in a mouse model of pulmonary 
fibrosis [109]. This therapy targeted idiopathic pulmonary fibrosis. It is known that telo-
meres act as protective structures at the ends of chromosomes and the presence of short 
telomeres has been shown to be one of the causes for disease development. In this condition, 
telomeres become too short, resulting in the cessation of cell division which in turn leads 
to cell apoptosis. Telomerase is an enzyme that can restructure the telomeres length, and 
Povedano and colleagues developed a treatment using AAV serotype 9 to deliver telom-
erase to correct the short telomeres. As AAV9 preferentially targets regenerative alveolar 
type II cells (ATII), AAV9-Tert-treated mice show improved lung function with reduced 
inflammation and fibrosis at 1–3 weeks after vector treatment. It is of interest to note that 
pulmonary fibrosis either improved or disappeared at 8 weeks of gene therapy. AAV9-Tert 
Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Disorders of Inherited…
http://dx.doi.org/10.5772/intechopen.80317
151
treatment lead to longer telomeres and increased proliferation of ATII cells, as well as lower 
DNA damage, apoptosis, and senescence.
AAV vector-derived cardiac gene therapy is emerging as an entirely new platform to treat car-
diac disorders [110]. AAV gene therapy for heart failure have been validated in preclinical stud-
ies using animal models, and the vast majority of these approaches have been undertaken to 
improve calcium handling by cardiomyocytes. The therapeutic protein used in the majority of 
these studies was sarcoplasmatic calcium ATPase (SERCA2a). Based on the positive preclinical 
findings, the first clinical trial (CUPID trial: calcium upregulation by percutaneous administra-
tion of gene vector in cardiac disease, NCT02346422) was carried out to deliver SERCA2a using 
AAV serotype 1 vector to treat patients with advanced heart failure [111, 112]. The outcome 
of this phase 1 trial was successful with no adverse events and was progressed to phase 2a 
study, providing promising outcomes with significantly low rate of adverse events. However, 
the results of phase 2b clinical trial (CUPID2b trial, NCT01643330) using the same vector were 
disappointing with no significant change between the treatment group and the placebo group 
[113]. This has led to the cessation of patient recruitment for two additional trials using AAV1.
SERCA2a [110]. Interestingly, there are two new upcoming trials aimed to deliver S100A1 with 
an AAV9 vector and a constitutively active form of the protein phosphatase 1 inhibitors, I1c, 
with a chimeric capsid with AAV2 and AAV8 serotypes [114, 115]. In addition, AAV1, AAV6, 
and AAV9 have emerged as the most promising AAV serotypes for cardiac gene transfer, which 
provides hopes for successful gene therapy approaches to treat heart failure in the future.
AAV-mediated gene therapy approaches to treat neuropathic pain in rodents have also been 
reported [116]. Fischer and colleagues have shown that administration of rAAV expressing Ca2+ 
channel-binding domain 3 (CBD3) gene significantly reduced pain behavior such as hyperalge-
sia after touch with a pin or sensitivity to acetone stimulation in animal models of inflammatory 
and neuropathic pain [117]. Another study using AAV9 vector encoding short hairpin RNA 
(shRNA) against vanilloid receptor 1 (TRPV1), which is an important target gene for acute pain, 
demonstrated that the therapy attenuated nerve injury-induced thermal allodynia (increased 
response of neurons) 10–28 days after treatment in a mouse model of spared nerve injury (SNI) 
[118]. These results provide positive evidence to encourage gene therapy researchers to develop 
AAV vector-based treatments for patients with chronic/diabetic neuropathic pain.
Considerable progress has been made in gene therapy approach to treat chronic liver fibrosis. 
Although angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers 
(ARBs) are widely used as treatments in patients with hypertension, they have been trialed 
in patients with chronic liver disease; however, the outcomes were not convincing mainly 
because they produce adverse systemic side effects [119]. Because of the lack of medical treat-
ments, liver transplantation has inevitably become the only option for patients with end stage 
liver disease, resulting from chronic hepatic fibrosis and/or cirrhosis. Moreover, increasing 
incidence of chronic liver disease, lack of donor organs, post-transplantation complications, 
and the high cost in liver transplantation mean that there is a major need to discover and 
formulate specific, effective, safe, and inexpensive novel therapies for liver fibrosis/cirrhosis.
One possible approach to circumvent this is to develop organ-targeted antifibrotic strategies. 
Studies from our laboratory suggested that one possible target is the “alternate axis” of the 
renin-angiotensin system (RAS), comprising its key enzyme angiotensin-converting enzyme 
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2 (ACE2), which breaks down the potent profibrotic octapeptide, angiotensin II (Ang II) to 
an antifibrotic heptapeptide, angiotensin-(1–7) (Ang-(1–7)) [120, 121]. Evidence from experi-
mental animal studies showed that recombinant human ACE2 (rhACE2) is beneficial for 
prevention of hypertension in cardiovascular disease [122] and to improve kidney function in 
diabetic nephropathy [123]. Interestingly, rhACE2 was well tolerated by a group of healthy 
human volunteers in a phase 1 clinical trial, without exerting any unwanted cardiovascular 
side effects [124]. There is one study that reported therapeutic effects of recombinant ACE2 in 
experimental liver fibrosis, in which liver injury was surgically induced by cholestasis or by 
hepatotoxic carbon tetrachloride injection [125]. They demonstrated that recombinant ACE2 
significantly reduced hepatic fibrosis in both animal models of liver disease [125]. However, 
a major drawback of this systemic approach is that the treatment inevitably produces off-
target effects, which in many cases are undesirable. Thus, there are several disadvantages 
with systemic administration of recombinant ACE2. This includes daily injections of ACE2, a 
procedure that is invasive in a clinical setting and expensive approach with unwanted effect 
on blood pressure regulation [125, 126]. To circumvent this problem, an ideal approach would 
be to increase tissue-specific ACE2 levels in the target organ. Thus, organ-specific increased 
ACE2 activity using a liver-specific recombinant AAV vector is expected to produce therapeu-
tic effects confined to the targeted organ while minimizing unwanted off-target effects.
In addition to the use of liver-specific capsid serotype, specificity can be further enhanced by 
engineering the vector with ACE2 gene under the transcriptional control of a strong liver-spe-
cific promoter, apolipoprotein E/human α1-antitrypsin. Studies published by our laboratory 
used a pseudotyped liver-specific AAV vector (rAAV2/8) for preclinical evaluation and found 
that hepatic overexpression of murine ACE2 gene delivered into the mice lasted for up to 
6 months following a single intraperitoneal injection [87]. We then treated mice with a range 
of liver disease models, which included biliary fibrosis induced by bile duct ligation (BDL), 
toxic injury induced by carbon tetrachloride (CCl4) injections, and fatty liver-associated liver 
fibrosis induced by feeding methionine- and choline-deficient (MCD) diet using a single intra-
peritoneal injection of rAAV2/8-ACE2 [87]. The treatment produced a major increase in ACE2 
expression and protein activity, which was confined to the liver without affecting other major 
organs. Unlike inherited disorders, for example, hemophilia B where a relatively low level of 
transgene expression in the liver may be sufficient for subsequent small increases in FIX levels 
in the blood [48, 81], the magnitude of the expression of transgene required for therapeutic 
intervention in non-inherited disease may be substantially higher. This, in turn, may pose a 
challenge for gene therapy researchers. Interestingly, however in our liver-targeted therapeu-
tic approach with rAAV2/8-ACE2, we found that increased hepatic ACE2 expression reduced 
hepatic level of profibrotic Ang II by more than 50% compared to those treated with a control 
vector that carried human serum albumin (rAAV2/8-HSA) [87]. A reduction of Ang II, which 
was accompanied by increases in hepatic levels of antifibrotic Ang-(1–7) peptide, resulted in 
a marked reduction in inflammatory cytokine expression, leading to a profound reduction in 
hepatic fibrosis in all three models (Figure 2) [87]. These studies with short-term animal mod-
els have been further validated to provide evidence that in long-term animal models of biliary 
fibrosis and fatty liver disease, which produce hepatic lesions more comparable to those seen 
in patients with such diseases, a single intraperitoneal injection of rAAV2/8-ACE2 caused a 
profound reduction in hepatic fibrosis (Figure 3). In marked contrast to other studies using 
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Figure 2. Hepatic ACE2 gene expression and fibrosis in three short-term models of liver fibrosis with rAAV2/8-ACE2 
therapy. ACE2 gene expression (A–C) was significantly increased (p < 0.0001) in ACE2-treated diseased mice compared 
to control vector (rAAV2/8-HSA) injected diseased mice of BDL, CCl4, and MCD. As a result, rAAV2/8-ACE2 gene 
therapy has markedly reduced the liver fibrosis in each mouse model (BDL, CCl4, and MCD).
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AAV vectors [93], we found that rAAV2/8-ACE2 reduced serum alanine transaminase (ALT) 
levels in diseased animals compared to those that received the control vector (rAAV2/8-HSA), 
suggesting that the vector itself is safe in the liver. Moreover, rAAV2/8-HSA (up to 10 days) 
or rAAV2/8-ACE2 (up to 24 weeks) vector injected into healthy mice produced no change in 
plasma ALT level, confirming that the vector itself is unlikely to cause liver injury [6, 87]. The 
schematic representation of molecular mechanism associated with ACE2 gene therapy using 
rAAV2/8 vector in hepatic fibrosis is shown in Figure 4.
Liver-targeted gene delivery using rAAV2/8 vector has shown to be therapeutically promis-
ing in adult liver, but their effects have not been extensively investigated in the immature 
liver. Although rAAV2/8 transduces neonatal mouse liver with high efficiency, the vector is 
not persistent in the liver and declines rapidly with liver growth [127]. Therefore, the success-
ful use of rAAV2/8-mediated therapy to treat liver disease in early childhood may require 
readministration [128]. In line with this, another study demonstrated that the treatment of 
ornithine transcarbamylase (OTC)-deficient neonatal mice with AAV2/8-OTC therapy failed 
to protect mice from hyperammonemia in adulthood [129]. Thus, producing stable transduc-
tion in the developing liver remains one of the biggest challenges for liver-specific rAAV2/8 
gene therapy, and readministration of vectors may be necessary to maintain therapeutic effi-
cacy in adulthood after early neonatal treatment.
Although the AAV vectors employed for preclinical studies may be effective in human 
liver, it is important to select an AAV vector specific for human hepatocytes with enhanced 
transduction efficiency [6, 55]. Recently, two groups have proposed using humanized mice 
such as the immunosuppressed FRG (Fah−/−/Rag2−/−/Il2rg−/−) mouse model to identify the 
best rAAV serotype for liver-directed gene therapy [55, 130]. The studies in humanized 
Figure 3. rAAV2/8-ACE2 therapy in Mdr2-KO mice with hepatic fibrosis. rAAV2/8-ACE2 gene therapy has markedly 
increased the ACE2 gene expression in Mdr2-KO mice, whereas liver fibrosis was significantly reduced by the therapy 
in ACE2-treated mice compared to the control vector-injected Mdr2-KO mice.
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Figure 4. rAAV2/8-ACE2 uptake by hepatocytes and a cascade of events triggered by ACE2 protein in activated hepatic 
stellate cells (HSCs) during fibrosis. rAAV-ACE2 particles use AAV receptor (AAV-R) on hepatocyte membrane to 
enter the cytoplasm, followed by translocation into nucleus where uncoating and releasing of single-stranded viral 
genome occurs. The complementary strand will then be synthesized to transcribe ACE2. Membrane bound ACE2 
protein has an exclusive role of cleaving potent profibrotic peptide angiotensin II (Ang II) to antifibrotic peptide 
angiotensin-1-7 (Ang-(1–7)). While a reduction in local Ang II levels leads to a significant reduction in the activation of 
its receptor, Ang II type 1 (AT1-R), Ang-(1–7) working through its receptor, Mas (Mas-R), inhibits the AT1-R activated 
downstream signaling such as PKC- and NADPH-mediated ROS production in activated HSCs. This in turn inhibits 
the phosphorylation of MAPKs such as ERK1/2, JNK, and p38, leading to a reduction in proinflammatory cytokines 
such as IL-1, IL-6, IL-8, IFNγ, MCP-1, and TNFα and profibrotic cytokine TGFβ1. A reduction in the activity of TGFβ1 
leads to a reduction in phosphorylation of its transcription factors, Smad2/3, resulting in the inhibition of secretion 
of matrix proteins such as collagens and fibronectins. Thus, rAAV-ACE2 helps improving hepatic fibrosis and thus, 
intrahepatic vascular tone, leading to an improvement in portal hypertension. PKC, protein kinase C; NADPH 
oxidase, nicotinamide adenine dinucleotide phosphate oxidase; IL, interleukin; IFNγ, interferon γ; MCP-1, monocyte 
chemotactic protein 1; TNFα, tumor necrosis factor α; TGFβ1, transforming growth factor-β1; ERK1/2, extracellular 
regulated kinase1/2; JNK, C-Jun N-terminal kinase.
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mouse model repopulated with over 25% human hepatocytes allowed the researchers 
to identify human liver-specific AAV vectors such as LK-03 derived from capsid DNA-
shuffled AAV library. This library was generated using 10 AAV capsid genes. LK-03, which 
is composed of five different parental AAV capsids, was able to transduce human primary 
hepatocytes at higher efficiency in vitro and in a hepatocellular carcinoma xenograft model 
in vivo when compared to AAV serotype 8 [55]. Wang and colleagues also reported a higher 
liver transduction level in FRG mice using capsid of AAVrh10, a clade E AAV derived 
from rhesus macaque, and AAV3B and have shown that AAV-LK-03 vectors may be supe-
rior to either AAV3B or AAV8 [131]. It is expected that researchers will increasingly use 
humanized animal models for diseases other than liver disease, which will allow them to 
identify novel variants of engineered AAV vectors, transduction efficiency, and immune 
reactions specific to the human tissue under investigation. Moreover, it has been reported 
that AAV3B-eGFP vector, which was able to cause liver-specific robust GFP expression 
in the livers of non-human primates, is significantly better than AAV8 with no apparent 
hepatotoxicity [132].
13. Conclusions
Much of preclinical studies which employed a diverse range of naturally occurring as well 
as engineered AAV vectors in the last decade provided ample evidence that therapeutic gene 
transfer certainly holds a great promise for patients with inherited disorders such as those that 
developed as a result of blood clotting factor deficiency and mutated retinal genes causing 
blindness. Moreover, it is now becoming clear that the findings of preclinical studies of non-
inherited disorders suggest that clinical studies utilizing therapeutic gene transfer is feasible.
Currently active clinical trials in patients with inherited disorders using a diverse range of 
AAV vector types will be expected to provide valuable insights into the safety and efficacy of 
AAV vectors [133]. Since the FDA as well as the EU has now endorsed human gene therapy, 
there is every possibility that the volume of gene therapy research employing next-generation 
AAV vectors for both inherited and non-inherited disorders in both preclinical and clinical 
settings would be expected to increase in the coming years. Moreover, a rapidly evolving 
technology of AAV vector engineering and the use of humanized animal models would be 
a key for rapid translation of preclinical findings to clinical studies. The findings from our 
ongoing liver fibrosis/cirrhosis work using human liver-specific AAV-LK-03 vector in human-
ized FRG mice would be expected to provide valuable information before we commence clini-
cal studies in patients with chronic liver disease.
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